Menu

Myrbetriq® (mirabegron) is a prescription medicine for adults used to treat overactive bladder (OAB) with symptoms of urgency, frequency and leakage.

Why Myrbetriq?

In this section, you'll learn about:

  • Treating OAB with Myrbetriq
  • How it works
  • Starting a conversation with your doctor
  • Possible side effects

What is Myrbetriq® (mirabegron)?

If you have OAB symptoms of urgency, frequency and leakage, ask your healthcare professional (HCP) if Myrbetriq may be right for you.

Myrbetriq is the first and only OAB treatment in its class

Myrbetriq is a prescription medicine approved
by the U.S. Food and Drug Administration (FDA)
to treat the OAB symptoms of urgency,
frequency and leakage in adults.

In clinical studies, it was found that patients taking Myrbetriq versus those not taking it:

  • experienced improvement in their OAB symptoms within the first several weeks
  • made fewer trips to the bathroom and had fewer leaks

Your results may vary.

If you have OAB symptoms of urgency, frequency and leakage, ask your healthcare professional (HCP) if Myrbetriq may be right for you.

How Myrbetriq Works

Myrbetriq works on a different pathway to increase bladder capacity

With OAB, the normal storage of urine in the bladder is interrupted when the bladder muscle suddenly contracts before the bladder is full, causing a sudden urgency to urinate that is frequent and cannot be controlled. These uncontrollable urges to urinate can sometimes lead to leakage—accidental wetting.

Myrbetriq is the only OAB treatment option in its class that targets the beta-3 pathway. When taken as directed, targeting this pathway can help relax the smooth muscle that surrounds
the bladder and increase the bladder's ability
to store urine.

If you take too many trips to the bathroom, have frequent leaks and accidents, or have already tried other options, your HCP may prescribe Myrbetriq for you.

See for yourself how Myrbetriq works

Watch these videos to learn more

How Myrbetriq Works Doctor Discussion

Myrbetriq: How It Works

Noted Urologist Dr. David Staskin
discusses
OAB and Myrbetriq

How Myrbetriq Works

How Myrbetriq Works in the Body

Watch an animated explanation of
Myrbetriq at work

Start the Conversation with Your Doctor

Take the OAB Symptoms Quiz

Talking with Your Doctor

If you are experiencing symptoms of OAB, talking with your doctor about them should be your first step. Here is a tool that will help you get started and make the most of your discussion. Using this tool is really simple!

1
Answer a few questions

2
Print or save the results

3
Show the results to your doctor

Get Started Now!

1. How many times do you urinate during the day?
2. Do you have to rush to the toilet to urinate?
3. Does urine leak before you can get to the toilet?
4. How much do these symptoms bother you?
Please complete the survey.
Next Start over
Find a specialist to talk to about your OAB symptoms
Powered by VITALS®

Possible Side Effects

Do not take Myrbetriq if you have an allergy
to mirabegron or any of the ingredients
in Myrbetriq.

Myrbetriq may cause serious side effects including:

Increased blood pressure:
Myrbetriq may
cause your blood pressure to increase or make
your blood pressure worse if you have a history
of high blood pressure. It is recommended that
your doctor check your blood pressure while
you are taking Myrbetriq.

Inability to empty your bladder
(urinary retention):
Myrbetriq may increase your
chances of not being able to empty your
bladder if you have bladder outlet obstruction
(BOO), or if you are taking other medicines to
treat OAB. Tell your doctor right away if you are
unable to empty your bladder.

Angioedema:
Myrbetriq may cause an allergic
reaction with swelling of the lips, face, tongue,
throat, with or without difficulty breathing. Stop
using Myrbetriq and tell your doctor right away.

Click on the side effect(s) to see the number of patients per 100 that were affected

Number that experienced side effect

Myrbetriq 50 mg
9.2 of 100
Active Control
9.6 of 100

Number that experienced side effect

Myrbetriq 50 mg
4.1 of 100
Active Control
2.5 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.8 of 100
Active Control
1.6 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.8 of 100
Active Control
8.6 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.7 of 100
Active Control
1.5 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.1 of 100
Active Control
2.0 of 100

Number that experienced side effect

Myrbetriq 50 mg
5.9 of 100
Active Control
6.4 of 100

Number that experienced side effect

Myrbetriq 50 mg
3.9 of 100
Active Control
3.1 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.8 of 100
Active Control
2.7 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.7 of 100
Active Control
2.6 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.6 of 100
Active Control
3.4 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.1 of 100
Active Control
2.3 of 100

Number that experienced side effect

Myrbetriq 50 mg
9.2 of 100
Active Control
9.6 of 100

Number that experienced side effect

Myrbetriq 50 mg
5.9 of 100
Active Control
6.4 of 100

Number that experienced side effect

Myrbetriq 50 mg
4.1 of 100
Active Control
2.5 of 100

Number that experienced side effect

Myrbetriq 50 mg
3.9 of 100
Active Control
3.1 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.8 of 100
Active Control
1.6 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.8 of 100
Active Control
2.7 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.8 of 100
Active Control
8.6 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.7 of 100
Active Control
2.6 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.7 of 100
Active Control
1.5 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.6 of 100
Active Control
3.4 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.1 of 100
Active Control
2.0 of 100

Number that experienced side effect

Myrbetriq 50 mg
2.1 of 100
Active Control
2.3 of 100

Tell your doctor if you have any side effect that bothers you or that does not go away or if you have swelling of the face, lips, tongue, or throat, hives, skin rash or itching while taking Myrbetriq. These are not all the possible side effects of Myrbetriq. For more information, ask
your doctor or pharmacist.

Approved for Combination Use

For adults with overactive bladder symptoms of urgency, frequency and leakage, Myrbetriq® (mirabegron) is FDA-approved for use in combination with solifenacin succinate.* Ask your doctor if this combination treatment may be right for you.

*Marketed in the US as VESIcare®

Myrbetriq Prescribing Information
Myrbetriq Patient Information
VESIcare® (solifenacin succinate) Prescribing Information
VESIcare® (solifenacin succinate)
Patient Information

What is MYRBETRIQ? MYRBETRIQ is a prescription medicine for adults that can be used alone or with solifenacin succinate to treat the following symptoms due to a condition called overactive bladder:

  • Urge urinary incontinence: a strong need to urinate with leaking or wetting accidents
  • Urgency: a strong need to urinate right away
  • Frequency: urinating often

It is not known if MYRBETRIQ, when used alone or with solifenacin succinate, is safe and effective in children.

How should I take MYRBETRIQ

  • If your doctor prescribes MYRBETRIQ and solifenacin succinate together, you should take 1 MYRBETRIQ tablet and 1 solifenacin tablet at the same time, 1 time a day.
  • You should take MYRBETRIQ with water and swallow the tablet whole.
  • Do not chew, break, or crush the tablet.
  • You can take MYRBETRIQ with or without food.
  • You can take MYRBETRIQ and solifenacin succinate together with or without food.

The most common side effects of MYRBETRIQ, when used with solifenacin succinate, include:

  • dry mouth
  • urinary tract infection
  • constipation
  • fast heartbeat

USE OF MYRBETRIQ Myrbetriq® (mirabegron) is a prescription medicine for adults that can be used alone or with solifenacin succinate to treat overactive bladder (OAB) with symptoms of urgency, frequency and leakage.

IMPORTANT SAFETY INFORMATION FOR MYRBETRIQ Myrbetriq is not for everyone. Do not take Myrbetriq if you have an allergy to mirabegron or any ingredients in Myrbetriq. Myrbetriq may cause your blood pressure to increase or make your blood pressure worse if you have a history of high blood pressure. It is recommended that your doctor check your blood pressure while you are taking Myrbetriq. Myrbetriq may increase your chances of not being able to empty your bladder. Tell your doctor right away if you have trouble emptying your bladder or you have a weak urine stream.

Myrbetriq may cause allergic reactions that may be serious. If you experience swelling of the face, lips, throat or tongue, with or without difficulty breathing, stop taking Myrbetriq and tell your doctor right away.

Tell your doctor about all the medicines you take including medications for overactive bladder or other medicines such as thioridazine (Mellaril™ and Mellaril-S™), flecainide (Tambocor®), propafenone (Rythmol®), digoxin (Lanoxin®), or solifenacin succinate (VESIcare®). Myrbetriq may affect the way other medicines work, and other medicines may affect how Myrbetriq works.

Before taking Myrbetriq, tell your doctor if you have liver or kidney problems. The most common side effects of Myrbetriq include increased blood pressure, common cold symptoms (nasopharyngitis), dry mouth, flu symptoms, urinary tract infection, back pain, dizziness, joint pain, headache, constipation, sinus irritation, and inflammation of the bladder (cystitis).

The most common side effects of MYRBETRIQ, when used with solifenacin succinate, include dry mouth, urinary tract infection, constipation, and fast heartbeat.

For further information, please talk to your healthcare professional and see accompanying Patient Product Information and complete Prescribing Information for Myrbetriq® (mirabegron).

USE OF VESICARE VESIcare® (solifenacin succinate) is for overactive bladder with symptoms of urgency, frequency, and leakage.

IMPORTANT SAFETY INFORMATION FOR VESICARE VESIcare is not for everyone. If you have certain stomach or glaucoma problems, or trouble emptying your bladder, do not take VESIcare. VESIcare may cause allergic reactions that may be serious. If you experience swelling of the face, lips, throat, or tongue, stop taking VESIcare and get emergency help. Tell your doctor right away if you have severe abdominal pain, or become constipated for three or more days. VESIcare may cause blurred vision, so use caution while driving or doing unsafe tasks. Common side effects are dry mouth, constipation, and indigestion.

For further information, please talk to your healthcare professional and see accompanying Patient Product Information and complete Prescribing Information for VESIcare® (solifenacin succinate).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.

Myrbetriq® and VESIcare® are registered trademarks of Astellas Pharma Inc. All other trademarks or registered trademarks are the property of their respective owners.

Next Section
What People Are Saying
Prev Section
Living With OAB
Previous:
Living With OAB
Next:
What People Are Saying

Use of Myrbetriq

Myrbetriq® (mirabegron) is a prescription medicine for adults used to treat overactive bladder (OAB) with symptoms of urgency, frequency and leakage.

Important Safety Information

Myrbetriq is not for everyone. Do not take Myrbetriq if you have an allergy to mirabegron or any ingredients in Myrbetriq. Myrbetriq may cause your blood pressure to increase or make your blood pressure worse if you have a history of high blood pressure. It is recommended that your doctor check your blood pressure while you are taking Myrbetriq. Myrbetriq may increase your chances of not being able to empty your bladder. Tell your doctor right away if you have trouble emptying your bladder or you have a weak urine stream.

Myrbetriq may cause allergic reactions that may be serious. If you experience swelling of the face, lips, throat or tongue, with or without difficulty breathing, stop taking Myrbetriq and tell your doctor right away.

Tell your doctor about all the medicines you take including medications for overactive bladder or other medicines such as thioridazine (Mellaril™ and Mellaril-S™), flecainide (Tambocor®), propafenone (Rythmol®), digoxin (Lanoxin®) or solifenacin succinate (VESIcare®). Myrbetriq may affect the way other medicines work, and other medicines may affect how Myrbetriq works.

Before taking Myrbetriq, tell your doctor if you have liver or kidney problems. The most common side effects of Myrbetriq include increased blood pressure, common cold symptoms (nasopharyngitis), dry mouth, flu symptoms, urinary tract infection, back pain, dizziness, joint pain, headache, constipation, sinus irritation, and inflammation of the bladder (cystitis).

For further information, please talk to your healthcare professional and see accompanying Patient Product Information and complete Prescribing Information for Myrbetriq® (mirabegron).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Myrbetriq® is a registered trademark of Astellas Pharma Inc. All other trademarks or registered trademarks are the property of their respective owners.

You are now leaving myrbetriq.com

You are now leaving myrbetriq.com. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
Continue to Twitter.

You are now leaving myrbetriq.com. The website you are linking to is not owned by Astellas. Astellas is not responsible for the services on this site.
Continue to Twitter.

You are now leaving myrbetriq.com. The website you are linking to is not owned by Astellas. Astellas is not responsible for the services on this site.
Continue to Facebook.

You are now leaving myrbetriq.com. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
Continue to FDA Medwatch.

You are now leaving myrbetriq.com. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
Continue to VITALS®.

Continue Cancel

This website is funded and developed by Astellas Pharma US, Inc. Myrbetriq is a registered trademark of Astellas Pharma Inc.

Our Doctor Conversation Guide can help you start the overactive bladder conversation.

Show it to your doctor at your appointment!

Get your Doctor Conversation Guide